Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Camille Gondran, Pierre-Yves Dumas, Audrey Bidet, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Isabelle Luquet, Émilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Eric Delabesse, Édouard Forcade, Cécile Borel, Arnaud Pigneux, Christian Recher, Laetitia Largeaud, Sarah Bertoli

Blood (2023) 142 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2023-180817

Published: 2023

Journal Articles

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Blood (2023) 142 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2023-182117

Published: 2023

Journal Articles

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Pierre Luc Mouchel, Sarah Bertoli, Emilie Berard, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Laetitia Largeaud, Nathan Guiraud, Jean-Emmanuel Sarry, Audrey Sarry, Francoise Huguet, Suzanne Tavitian, Christian Recher

Blood (2022) 140 (Supplement 1): 3239–3241.

https://doi.org/10.1182/blood-2022-166373

Published: 2022

Journal Articles

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Laetitia Largeaud, Sarah Bertoli, Emilie Berard, Suzanne Tavitian, Muriel Picard, Stephanie Dufrechou, Naïs Prade, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Audrey Sarry, Francoise Huguet, Jean Ruiz, Veronique De Mas, Eric Delabesse, Christian Recher

Blood (2021) 138 (Supplement 1): 1294.

https://doi.org/10.1182/blood-2021-147497

Published: 2021

Journal Articles

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

Ibrahim Didi, David Simoncini, Francois Vergez, Pierre-Yves Dumas, Suzanne Tavitian, Laetitia Largeaud, Audrey Bidet, Jean-Baptiste Rieu, Isabelle Luquet, Nicolas Lechevalier, Eric Delabesse, Audrey Sarry, Anne-Charlotte De Grande, Emilie Berard, Arnaud Pigneux, Christian Recher, Jean-Marc Alliot, Sarah Bertoli

Blood (2021) 138 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2021-145122

Published: 2021

Journal Articles

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Pierre Bories, MD, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2018-99-117219

Published: 2018

Journal Articles

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Emilie Berard, MD, Noemie Gadaud, Audrey Sarry, Francoise Huguet, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2018) 132 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2018-99-113109

Published: 2018

Journal Articles

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Pierre Bories, MD, Naïs Prade, Bastien Cabarrou, Stéphanie Lagarde, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2018-99-117336

Published: 2018

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 1718.

https://doi.org/10.1182/blood.V128.22.1718.1718

Published: 2016

Journal Articles

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Christian Récher, MD PhD, Sarah Bertoli, MD PhD, Muriel Picard, MD, Emilie Bérard, MD PhD, Clément Larrue, PhD, Suzanne Tavitian, MD, Francois Vergez, DVM, PhD, Edwige Yon, Jean Ruiz, MD, Eric Delabesse, PharmD, PhD, Isabelle Luquet, MD, Laetitia Linares, PhD, Martin Carroll, MD, Audrey Sarry, Françoise Huguet, MD, Jean-Emmanuel Sarry, PhD

Blood (2016) 128 (22): 1636.

https://doi.org/10.1182/blood.V128.22.1636.1636

Published: 2016

Journal Articles

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Sarah Bertoli, MD PhD, Noemie Gadaud, Suzanne Tavitian, MD, Audrey Sarry, Emilie Bérard, MD PhD, Françoise Huguet, MD, Christian Recher, MD PhD

Blood (2016) 128 (22): 3991.

https://doi.org/10.1182/blood.V128.22.3991.3991

Published: 2016

Journal Articles

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Sarah Bertoli, MD PhD, Emilie Bérard, MD PhD, Suzanne Tavitian, MD, Anne Huynh, MD, Cecile Borel, MD, Sarah Guenounou, Isabelle Luquet, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Guy Laurent, MD PhD, Michel Attal, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 3996.

https://doi.org/10.1182/blood.V128.22.3996.3996

Published: 2016

Journal Articles

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

Sarah Bertoli, Emilie Bérard, Françoise Huguet, Anne Huynh, Suzanne Tavitian, François Vergez, Sophie Dobbelstein, Nicole Dastugue, Véronique Mansat-De Mas, Eric Delabesse, Eliane Duchayne, Cécile Demur, Audrey Sarry, Valérie Lauwers-Cances, Guy Laurent, Michel Attal, Christian Récher

Blood (2013) 121 (14): 2618–2626.

https://doi.org/10.1182/blood-2012-09-454553

Published: 2013

Includes: Supplemental data

NARROW

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only